Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (TERN)
NASDAQ:TERN
TERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.87 - $11.00
Previous CloseN/A
Volume294.76K
Average Volume (3M)1.13M
Market Cap
$637.08M
Enterprise Value$27.26M
Total Cash (Recent Filing)$315.44M
Total Debt (Recent Filing)$1.13M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 18, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding87,511,050
10 Day Avg. Volume1,079,514
30 Day Avg. Volume1,134,384
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-252.43
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$13.69Price Target Upside81.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe Part 2 dose expansion of the '701 Ph1 CARDINAL trial in CML initiated, showing progress in clinical trials.
Financial StabilityCash of $358M gives runway to 2028, providing financial stability for the company.
Market PotentialThe potential of oral GLP-1 drugs in development is highly bullish for Terns Pharmaceuticals, Inc., potentially explaining the recent rise in TERN shares.
Bears Say
Competitive ConcernsQuestions may emerge on the competitive profiles of oral GLP-1's versus injectable GLP-1's and their potential positioning in the market.
Data LimitationsIt is difficult to draw solid conclusions at this point based on 10 non-T315I mutated patients.
Terns Pharmaceuticals News
TERN FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was $1.86 and its highest was $11.00 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Terns Pharmaceuticals’s market cap is $637.08M.
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is Nov 18, 2025 which is in 67 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.03.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -0.3.
How many shares outstanding does Terns Pharmaceuticals have?
Terns Pharmaceuticals has 87,511,050 shares outstanding.
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -6.743%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Currently, no hedge funds are holding shares in TERN
Terns Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.69 (81.32% Upside)
$13.69 (81.32% Upside)
Blogger Sentiment
Bullish
TERN Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 989.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $92.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.21%
12-Months-Change
Fundamentals
Return on Equity
-35.02%
Trailing 12-Months
Asset Growth
38.78%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
TERN Stock 12 Month Forecast
Average Price Target
$13.69
▲(81.32% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
Protalix
―
DBV Technologies SA - American
―
Gossamer Bio
―
Foghorn Therapeutics
―
Ownership Overview
0.77% Insiders
9.19% Mutual Funds
47.85% Other Institutional Investors
33.47% Public Companies and
Individual Investors